Knight Therapeutics Announces Q1 Growth and Expansion
Company Announcements

Knight Therapeutics Announces Q1 Growth and Expansion

Knight Therapeutics (TSE:GUD) has released an update.

Knight Therapeutics Inc. has reported a 5% revenue growth to $86.6 million in the first quarter of 2024, driven by key product sales but offset by a 25% decrease in adjusted EBITDA due to higher marketing expenses for new product launches. Despite the net loss widening slightly from the previous year, the company saw a substantial 616% increase in cash flow from operations due to strong operating results and improved working capital management. The company has also expanded its portfolio with the launch of new products in Canada and Brazil, and by in-licensing and regulatory approvals in Latin America.

For further insights into TSE:GUD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyKnight Therapeutics price target lowered to C$6.25 from C$6.75 at Stifel
TipRanks Auto-Generated NewsdeskKnight Therapeutics Reports Q3 2024 Financial Results
TheFlyKnight Therapeutics downgraded to Hold from Buy at Mackie Research Capital
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App